DrugPatentWatch Database Preview
ADDYI Drug Profile
Which patents cover Addyi, and what generic alternatives are available?
Addyi is a drug marketed by Sprout Pharms and is included in one NDA. There are four patents protecting this drug.
This drug has eighty-one patent family members in thirty-one countries.
The generic ingredient in ADDYI is flibanserin. One supplier is listed for this compound. Additional details are available on the flibanserin profile page.
Summary for ADDYI
| International Patents: | 81 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 43 |
| Patent Applications: | 249 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ADDYI |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for ADDYI |
| DailyMed Link: | ADDYI at DailyMed |
Generic Entry Opportunity Date for ADDYI
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ADDYI
| Mechanism of Action | P-Glycoprotein Inhibitors |
Synonyms for ADDYI
| 1-(2-(4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)ethyl)-1H-benzo[d]imidazol-2(3H)-one |
| 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one |
| 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-(piperazinyl)ethyl)-2-benzimidazolinone |
| 1-(2-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}ethyl)-1,3-dihydro-2H-benzimidazol-2-one |
| 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one |
| 167933-07-5 |
| 2H-Benzimidazol-2-one, 1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]- |
| 2H-Benzimidazol-2-one,1,3-dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]- |
| 3-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-1H-benzimidazol-2-one |
| 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one |
| 37JK4STR6Z |
| 933F075 |
| A810922 |
| AC1OCF7H |
| Addyi (TN) |
| AKOS005146139 |
| AM84577 |
| API0006409 |
| AT-16920 |
| BCP02131 |
| Bimt 17 |
| BIMT 17 BS |
| Bimt-17 |
| BIMT-17-BS |
| CHEBI:90865 |
| CHEMBL231068 |
| CS-4671 |
| D02577 |
| DB04908 |
| Female Viagra (Street Name) |
| Female Viagra [Street Name] |
| Flibanserin |
| Flibanserin (USAN/INN) |
| Flibanserin [USAN:INN] |
| FT-0659246 |
| Girosa |
| Girosa (proposed trade name) |
| GTPL8182 |
| HSDB 8278 |
| HY-A0095 |
| KS-00000293 |
| L001463 |
| MolPort-006-170-023 |
| NCGC00386567-01 |
| SC-28449 |
| SCHEMBL247579 |
| UNII-37JK4STR6Z |
| ZINC52716421 |
US Patents and Regulatory Information for ADDYI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sprout Pharms | ADDYI | flibanserin | TABLET;ORAL | 022526-001 | Aug 18, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Sprout Pharms | ADDYI | flibanserin | TABLET;ORAL | 022526-001 | Aug 18, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Sprout Pharms | ADDYI | flibanserin | TABLET;ORAL | 022526-001 | Aug 18, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
